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Abstract
Purpose of the Review Acute heart failure (AHF) is a
life-threatening clinical condition that requires prompt medical
attention. The aim of the current review is to summarise the
results of recent clinical trials conducted in patients with AHF.
Recent Findings Several novel compounds have apparently
beneficial acute effects on cardiovascular haemodynamics
and patients’ symptoms, but their administration has not yet
translated into improved survival and has been deleterious in
some cases.
Summary The management of patients with AHF is challeng-
ing and reflects the heterogeneity of patient’s presentation, the
complexity and severity of a multi-organ syndrome, and the
limited therapeutic options, usually restricted to a combination
of diuretics and vasodilators. Ongoing trials of novel treat-
ments may provide evidence of an effect on outcomes.
Keywords Acute heart failure . Pharmacological treatments .
Non-pharmacological treatments . Dyspnoea at rest
Introduction
Acute heart failure (AHF) is a life-threatening clinical condi-
tion that requires prompt medical attention [1•]. For patients
with chronic heart failure due to left ventricular systolic dys-
function, there is a huge wealth of data demonstrating un-
equivocally that some interventions improve survival and
symptoms. The cumulative effect of modern therapy has a
dramatic effect on survival. By contrast, there is still no good
evidence that any treatment for acute heart failure improves
prognosis. How has this come about?
Patients presenting with AHF are heterogeneous. Many clini-
cians asked to describe a notional patient with AHF describe a
patient with acute pulmonary oedema. However, pulmonary oe-
dema is a less common presentation thanmight be thought: most
patients presenting with acute heart failure do so because they
have fluid retention (and peripheral oedema) as their dominant
symptom; they are not short of breath at rest [2, 3].
Clinical trials in patients with AHF often aim to recruit
patients who have resting breathlessness (which seems to sug-
gest the intention to recruit patients with pulmonary oedema)
[4••, 5••]. However, the trial entry criteria often then seek to
exclude those with an obvious precipitant for their pulmonary
oedema, such as acute ischaemia or an arrhythmia. This cre-
ates a problem: almost by definition, acute pulmonary oedema
has a precipitant of some sort.
A related issue is that patients with acute pulmonary oede-
ma often present out-of-hours, at a time when it is difficult to
go through complex trial procedures and when research staff
are often not at work. Such patients are often extremely un-
well, and not well placed to give informed consent prior to
trial entry.
The treatment for acute pulmonary oedema may not have
changed much for 40 years, but nor has the natural history:
with standard treatment (usually an intravenous loop diuretic
and perhaps a nitro vasodilator), patients often rapidly recover
[6]. A consequence for a clinical trialist interested in, say,
relief of breathlessness as a primary endpoint is that by the
time a patient is recruited, many hours have passed since the
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initial presentation, by which time the patient’s symptoms
have largely settled.
The majority of patients presenting with AHF have fluid
retention rather than pulmonary oedema (although may obvi-
ously have pulmonary congestion). In such patients, an intra-
venous diuretic given over many days is the standard treat-
ment. There have been few clinical trials designed to test treat-
ments in this clinical scenario.
The current European Society of Cardiology (ESC) guide-
lines for the management of acute heart failure stress that
diagnosis and identification of precipitants should take place
in parallel with treatment.1 However, most of the treatments
for AHF are still opinion, rather than evidence, based. Several
promising therapies have been shown to improve cardiovas-
cular haemodynamics and patients’ symptoms, but the acute
effects have not yet been shown to translate into improved
survival; some have actually been deleterious [7••, 8]. The
aim of the present review is to discuss some of the novel
agents and interventions which might have a future role in
the management of patients with AHF.
Current Treatments
Intravenous loop diuretics are the cornerstone of treatment of
congestion in patients with AHF. However, it is still not clear
what the best treatment regime might be. In the DOSE trial,
patients admitted with AHF with a blood pressure greater than
90 mmHg were randomised to a low (total intravenous furo-
semide dose equal to previous daily oral dose) or a high dose
of loop diuretic (total daily intravenous furosemide dose 2.5
times previous daily oral dose), either given as a bolus or
continuous infusion. There was no significant difference ei-
ther for the safety endpoint of worsening renal function or the
efficacy endpoint of global assessment of symptoms between
these groups. However, patients receiving higher doses had a
greater mean weight loss and mean fluid loss, at a price of
some transient worsening in renal function [9•]. The current
ESC-HF guidelines recommend the smallest dose of diuretic
required to provide clinical effect [1•].
Vasodilators are the secondmost commonly used treatment
in patients with AHF, especially in the hypertensive patient,
and particularly in those patients with pulmonary oedema.
Registries suggest that they are used in only around one out
of five patients with AHF [1•, 10]. Nearly 20 years ago, Cotter
and colleagues randomised patients with pulmonary oedema
to high-dose isosorbide dinitrate (3 mg bolus administered
intravenously every 5 min) or high-dose furosemide (80 mg
bolus administered intravenously every 15 min) plus
isosorbide dinitrate (dose of 1 mg/h). Compared with
low-dose nitrates, high-dose nitrates decreased myocardial in-
farction (MI) and the need for mechanical ventilation without
any effect on mortality. Higher dose of nitrates was also
associated with a lower heart rate (HR), higher oxygen satu-
ration, and lower respiratory rate [11•].
Some patients with AHF may present with a low blood
pressure or in shock. In these scenarios, a prompt identifica-
tion of precipitating cause (for instance, an acute myocardial
infarction, or pulmonary embolism) is paramount. For those
cases in whom cardiac output is severely reduced and organ
perfusion is compromised, vasopressors, like noradrenaline,
and inotropes, like levosimendan or dobutamine, can be used
with caution. However, such evidence as there is from
randomised trials suggests that the use of positive inotropic
agents is associated with a worse prognosis [12]. In selected
cases that do not stabilise despite inotropic support, mechan-
ical circulatory support or urgent heart transplant may be con-
sidered [1•].
Recent Advances in Heart Failure Treatment
Given the high mortality and economic burden of patients
admitted with AHF, and the lack of effective drugs, other than
those mentioned above, there is an urgent need for novel ther-
apies and better clinical trial designs [4••]. When designing
clinical trials for novel therapies in AHF, several factors need
to be considered. As well as patient heterogeneity, “standard”
therapy for AHF is not standardised, leading to potentially
very variable treatment of patient in the control arms of stud-
ies. Clinical trials often use short-term primary endpoints,
such as changes in symptoms, which are susceptible to patient
or physician subjective bias [13]. On the other hand, it is
difficult to picture how the single administration of a drug
given at presentation might affect more robust (and perhaps
clinically important) endpoints, such as early heart failure re-
admission and short-term (30–180 days) survival [5••].
Pharmacological Therapies
Natriuretic Peptides
Nesiritide
Nesiritide is recombinant human brain natriuretic peptide
(BNP). It has vasodilatory effects on the arteries and veins,
enhances sodium excretion, and supresses both the
renin-angiotensin-aldosterone and sympathetic nervous sys-
tems [14] (Fig. 1).
The VMAC study was very influential in getting nesiritide
licenced for use in the USA. In VMAC, 432 patients with
AHF were randomised to receive nesiritide, nitrate, or place-
bo. Nesiritide reduced pulmonary capillary wedge pressure
and improved both dyspnoea and global status as assessed
by a physician [15] (Table 1). However, nesiritide did not
improve symptoms or mortality when compared to standard
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vasoactive medications [15]. In large part, because European
authorities were reluctant to accept haemodynamic data as
being sufficiently definitive to allow licencing, a large
(>7000 patients) study, ASCEND-HF, was conducted in pa-
tients presenting with pulmonary congestion. Compared to
placebo, nesiritide did not improve 30-day all-cause mortality,
rehospitalisation for heart failure, or renal function. However,
patients treated with nesiritide were more likely to have epi-
sodes of hypotension compared to placebo (26.6% nesiritide
vs. 15.3% placebo, p < 0.001) [16]. Current guidelines do not
endorse neseritide as a treatment of AHF [1•] (Table 1).
Ularitide
Another endogenous natriuretic peptide, urodilatin, is pro-
duced in the kidneys. It binds to natriuretic peptide type A
receptors in the inner medullary collecting duct. It increases
intracellular cyclic guanosine monophosphate (cGMP) which
inhibits sodium reabsorption via an amiloride-sensitive chan-
nel. Ularitide is a synthetic version of urodilatin [17] (Fig. 1).
The phase IIa randomised double-blind SIRIUS I study
enrolled 24 patients; compared to placebo, both 15- and
30-ng/kg/min doses of ularitide decreased pulmonary capil-
lary wedge pressure (PCWP), right atrial pressure (RAP), and
N-terminal pro BNP from baseline [18] (Table 1).
A subsequent phase IIb (SIRIUS II) randomised,
double-blind, placebo-controlled trial in 221 patients with
AHF who had low cardiac index (<2.5 l/min) and raised
PCWP (≥18 mmHg) found that ularitide was associated with
a rapid and significant decrease in PWCP and, at higher doses,
systemic vascular resistance (SVR) [19] (Table 1). There was
no effect of ularitide on renal function during the 24-h infusion
and in the 48 h of follow-up, but some patients in the 30 ng/kg/
min infusion group (N = 7, 13%) had their drug temporarily
interrupted due to hypotension [20]. Whether ularitide im-
proves clinical status and 180-day survival in patients with
decompensated heart failure is currently under evaluation in
the TRUE AHF (NCT01661634).
Inotropic Agents
Levosimendan
Levosimendan sensitises troponin C to calcium thereby im-
proving myocardial contractility and haemodynamics.
Levosimendan also has vasodilatory and anti-ischaemic prop-
erties [21] (Fig. 1).
Early data from LIDO suggested that compared to dobuta-
mine, levosimendan improved cardiac haemodynamics and
30- and 180-day mortality [21] (Table 1). The effect on mor-
tality was not confirmed in the larger SURVIVE trial
(N = 1327 patients) [22]. More recently, in the REVIVE study,
levosimendan was compared to placebo in 700 patients with
AHF with a mean LVEF of 23%, who remained dyspnoeic at
rest despite treatment with intravenous diuretics and in some
cases vasodilators (13%) or inotropes (11%). Compared to
placebo, levosimendan had a greater symptomatic improve-
ment, but led to a higher incidence of hypotension, higher
heart rate, and subsequent risk of developing atrial and ven-
tricular arrhythmias, thus increasing the risk of death [23].
The current ESC guidelines on heart failure recommend
levosimendan in cardiogenic shock in combination with other
vasopressors and over dobutamine only if reversal of
beta-blockers is need to improve the hypoperfusion [1•].
Istaroxime
Istaroxime is a novel intravenous agent which both inhibits
sodium/potassium ATPase (much as cardiac glycosides) and
stimulates sarcoplasmic reticulum calcium adenosine
triphosphatase isoform 2a (SERCA2a), thereby stimulating
the re-uptake of calcium into the sarcoplasmic reticulum dur-
ing diastole. The combined mechanism of action means that
Fig. 1 Novel therapies in acute
decompensated heart failure.
CPAP continuous positive airway
pressure, NIPPV non-invasive
positive pressure ventilation
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istaroxime has both inotropic and lusitropic properties [24]
(Fig. 1).
A phase II, randomised, controlled trial (HORIZON-HF)
evaluated the short-term effects of istaroxime in 120 patients
with AHF and a left ventricular ejection fraction ≤35%.
Compared to placebo, all doses of istaroxime (0.5, 1.0, and
1.5 μg/kg/min) caused a fall in PCWP and heart rate and
increased systolic blood pressure. Although istaroxime re-
duced left ventricular volumes, and indices of diastolic func-
tion on echocardiography from baseline, compared to place-
bo, there was no significant change in these variables [24]
(Table 1). Vomiting and pain at the infusion site were the most
common side-effect reported. A study aiming to recruit 120
patients with AHF with LVEF less than 40%, who are admit-
ted with dyspnoea at rest or minimal exertion needing intra-
venous diuretics, is currently planned. The primary endpoint
is change of diastolic function (E/Ea ratio assessed by tissue
Doppler on echocardiography) (NCT02617446).
Other Novel Pharmacological Agents
Serelaxin
Serelaxin is a recombinant form of the naturally occurring
relaxin-2 involved with the adaptation of cardiovascular and
renal function during pregnancy [25] (Fig. 1).
In the Pre-RELAX-AHF study, 230 patients with
AHF (admitted with dyspnoea at rest or on minimal
exertion, evidence of pulmonary congestion on chest
radiography, raised natriuretic peptides, and a systolic
blood pressure >125 mmHg) were randomised to stan-
dard care followed by 48-h intravenous infusion of pla-
cebo (n = 62) or different doses of serelaxin (10, 30,
100, or 250 μg/kg per day). Compared to placebo, pa-
tients randomised to 30-μg/kg/day dose had the greatest
improvement in shortness of breath and resolution of
signs of congestion (physician-assessed jugular venous
pressure, rales, and oedema), reduction in body weight,
and use of intravenous diuretics [25]. A subsequent
phase III trial (RELAX-AHF) of 1161 patients with
AHF, recruited within 16 h of admission with dyspnoea
at rest, pulmonary congestion of chest X-ray raised plas-
ma levels of natriuretic peptides, and mild to moderate
impaired renal dysfunction, compared the infusion of
30 μg/kg/day for 48 h to placebo. Serelaxin improved
breathlessness slightly more than placebo, although it
was difficult to understand the clinical significance. In
a post hoc analysis, there was a 37% reduction in
all-cause mortality at 180 days [26]. In a sub-analysis
of the trial, Metra and colleagues also reported a signif-
icant reduction in NTproBNP, high-sensitivity troponin
T, and incidence of worsening renal function (serum
creatinine increase of 0.3 mg/ or a cystatin C increaseTa
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of 0.3 mg/l) at day 2 in those randomised to serelaxin
[27]. The results are by no means definitive. Several
patients were lost to follow-up and the mortality effect
was of borderline statistical significance (Table 1). A
large, multicentre, phase III trial (RELAX-AHF-2) is
currently ongoing and plans to recruit more than 6000
patients. The primary endpoints are cardiovascular death
first occurrence of worsening heart failure.
TVR027
The angiotensin II type 1 receptor (AT1R) is a G
protein-coupled receptor that mediates the biological effects
of angiotensin II. There are two pathways down-stream from
the receptor: firstly, signalling mediated via Gq protein causes
vasoconstriction and cardiac hypertrophy. and secondly, sig-
nalling mediated via β-arrestin-2 causes modest inotropic and
cardioprotective effects (stimulation of cardiomyocyte prolif-
eration, activation of the pro survival kinase, Akt, and reduc-
tion in apoptosis). Angiotensin receptor blockers block both
signalling pathways: Gq, causing reduction in vascular tone,
andβ-arrestin-2, causing reduction in cardiac contractility and
cardio protective effects. TRV027 is a novel β-arrestin-biased
antagonist of the AT1R, meaning that it antagonises the Gq
protein pathway whilst stimulating β-arrestin-2 [28] (Fig. 1).
In a study by Soergel and colleagues in patients with chron-
ic heart failure, compared to placebo, TVR027 caused a
dose-dependent decrease in PCWP with no change in cardiac
index (CI) and a reduction in mean arterial pressure [29]
(Table 1). The BLAST-AHF is a phase II study in which
approximately 500 patients with AHF and systolic blood pres-
sure ≥120 mmHg will be randomised to different doses of
intravenous TRV027 (1, 5, or 25 mg/h) or placebo for at least
48 h, and up to 96 h, to evaluate its efficacy on symptoms and
plasma levels of natriuretic hormones [28].
Omecamtiv Mecarbil
Omecamtiv mecarbil is a selective cardiac myosin activator
which increases myocardial contractility without increasing
myocardial oxygen demand [30] (Fig. 1). In the
ATOMIC-AHF study, conducted in 606 patients with AHF,
LVEF <40%, and raised natriuretic peptides, the use of
omecamtiv mecarbil did not have influence symptoms or mor-
tality compared to placebo [30]. Although it increased left
ventricular systolic ejection time and reduced end-systolic
LV dimension, those randomised to omecamtiv mecarbil had
higher troponin levels at 48 h [30]. Nevertheless, side-effects
were the same as placebo (Table 1). The results of
COSMIC-HF study which compared omecamtiv mecarbil to
placebo in 544 patients with heart failure with reduced ejec-
tion fraction and raised BNP are awaited (NCT01786512).
Rolofylline
Patients with AHF with worsening renal function have a poor
prognosis. Adenosine acts on the adenosine A1 receptors in
the renal arterioles to reduce renal blood flow thereby reduc-
ing glomerular filtration rate and increasing renin production.
Stimulation of the adenosine A1 receptors also increases so-
dium reabsorption in proximal tubule. Antagonising the aden-
osine A1 receptor by rolofylline might thus improve renal
blood flow, perhaps improving renal function and diuresis
[31] (Fig. 1).
In the PROTECT pilot study, different doses rolofylline or
placebo were administered daily for up to 3 days in patients
with AHF; those who received the 30-mg dose of rolofylline
had a greater relief of dyspnoea and less worsening of renal
function, compared to placebo [31].
These results were not confirmed in a subsequent phase III
trial enrolling >2000 patients, in which 30 mg of rolofylline or
placebo was administered as a 4-h intravenous infusion daily
for (up to 3 days). Seizures being more common in rolofylline
group [32] (Table 1). There will, unfortunately, continue to be
no direct treatment for renal dysfunction in patients with AHF.
Dopamine
Worsening renal failure is common in patients with AHF.
Dopamine is an endogenous catecholamine and, at low doses,
increases glomerular filtration rate by vasodilation of renal
blood vessels [33, 34] (Fig. 1).
In the DAD-HF study, 60 patients with a mean LVEF of
35%, admitted with recent onset of dyspnoea (<6 h) with other
signs of congestion, were randomised to either high-dose fu-
rosemide or low-dose furosemide combined with low-dose
dopamine. The combination of low-dose furosemide and
low-dose dopamine had significantly lower incidence of wors-
ening renal function (>0.3-mg/dl rise in serum creatinine from
baseline to 24 h). The mean hourly urine output and the dys-
pnoea scores were similar in both groups but there was no
difference in 60-day mortality and rehospitalisation [35]. To
answer the question of whether low-dose furosemide or dopa-
mine reduce the incidence of worsening renal function, the
DAD-HF II study of 161 patients included patients on
low-dose furosemide on its own. High-dose furosemide had
an increased incidence of worsening renal function compared
to low-dose furosemide, with or without dopamine [36]
(Table 1).
In the ROSE AHF study, 360 patients admitted with AHF
regardless of LVEF who had at least one symptom (dyspnoea,
orthopnoea, or oedema) and one sign (rales, oedema, ascites,
or pulmonary vascular congestion on chest radiography) of
acute heart failure, renal dysfunction (glomerular filtration rate
of 15–60 ml/min/1.73 m2), and on background diuretic thera-
py were randomised to dopamine, nesiritide, or placebo.
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Compared to placebo, dopamine did not affect the 72-h cu-
mulative urine volume, change in cystatin C level at 72-h or
60-day mortality, and readmission with heart failure [34]
(Table 1).
Tolvaptan
In many patients with AHF, loop diuretics cause
hyponatraemia, a poor prognostic sign, and a feature suggest-
ing that diuretic therapy is likely to fail. An agent that en-
hances water excretion whilst having no effect on sodium
excretion (an aquaretic) might thus be beneficial. Tolvaptan
is an oral vasopressin-2 receptor antagonist which inhibits anti
diuretic hormone leading to excretion of free water [37]
(Fig. 1).
However, in the large EVEREST trial (N = 4133 patients),
compared to placebo, tolvaptan did not reduce the primary
endpoints of all-cause mortality and combined cardiovascular
death and rehospitalisation due to heart failure, although it
improved symptoms and serum sodium levels, without in-
creasing adverse events [37]. In TACTICS-HF, 257 patients
with AHF, regardless of LVEF admitted with dyspnoea at rest
and one other sign or symptom of congestion (orthopnoea,
oedema, elevated jugular venous pulse, rales, or congestion
on chest radiograph), were randomised to receive three doses
of tolvaptan over 48 h in addition to standardised background
furosemide therapy. Whilst tolvaptan caused greater weight
loss (tolvaptan −3.7 (4.4) kg vs placebo −2.5 (3.2) kg,
p = 0.07), it did not affect fluid loss (tolvaptan 1757 (1670)
ml vs placebo 1401 (1387), p = 0.11)) or symptoms, and was
associated with a higher chance of worsening renal function
[38] (Table 1).
The current ESC guidelines on HF advise considering
tolvaptan in AHF in patients with volume overload and resis-
tant hyponatraemia [1•]. The vasopressin antagonists have not
yet found a clearly defined role in managing patients with
heart failure. It is possible that theymay be particularly helpful
in patients with marked hyponatraemia, but the right trial has
not yet been conducted.
Non-pharmacological Therapies
Ventilatory Support: Oxygen and Non-invasive
Ventilation
Oxygen has been used liberally pre hospital and in the emer-
gency departments in the perception that it relieves dyspnoea
and improves myocardial oxygenation despite normal oxygen
saturation. However, supplemental oxygen and assisted ven-
tilation should be reserved for patients with hypoxaemia. In
the very few studies that have systematically examined the
effects of increasing FiO2, oxygen supplementation causes a
fall in cardiac output and increases in SVR and cardiac filling
pressures [39] (Fig. 1).
In a study by Gray and colleagues, 1069 patients with AHF
admitted with cardiogenic pulmonary oedema and arterial pH
of less than 7.35 were randomised to standard oxygen therapy,
continuous positive airway pressure (CPAP), or non-invasive
intermittent positive pressure ventilation (NIPPV). Compared
to standard oxygen therapy, non-invasive ventilation (both
CPAP and NIPPV) did not alter 7- and 30-day mortality, but
did lead to greater reduction in dyspnoea, heart rate, and hy-
percapnia [40] (Table 1). A subsequent meta-analyses on the
use of non-invasive positive pressure ventilation (NIPPV)
showed a reduction in hospital mortality compared to standard
treatment [41, 42].
Ultrafiltration
Ultrafiltration (UF) can be used to remove the excess salt and
fluid of patients with fluid retention, even if they are resistant
to high doses of diuretics. In the UNLOAD trial, which tested
the safety and efficacy of veno-venous ultrafiltration versus
standard diuretic therapy in 200 congested patients with AHF,
ultrafiltration had a more pronounced effect on weight reduc-
tion and fluid loss than standard therapy, and was associated
with a decrease in 90-day rehospitalisation for HF [43]
(Fig. 1).
In a subsequent study, CARRESS-HF, conducted in 188
patients with AHF with signs of congestion (at least two
criteria: 2+ peripheral oedema, or more; jugular venous pres-
sure greater than 10 cm of water; or pulmonary oedema or
pleural effusion on chest radiography) and worsening renal
function (increase in the serum creatinine level of at least
0.3 mg per decilitre) compared to standard pharmacological
therapy, UF led to a worsening in renal function with no sig-
nificant difference in weight loss between the two groups [44].
There was a higher number of adverse events in the ultrafil-
tration group, mainly due to increased incidences of kidney
failure, bleeding, and catheter complications, but the deterio-
ration in renal function could simply be due to serum concen-
tration (Table 1).
Recently, the AVOID-HF trial was terminated early by the
sponsor when 224 of the 800 planned patients with AHF had
been enrolled. Patients had to have at least two signs of con-
gestion (pitting oedema ≥2+ of the lower extremities, jugular
venous distension >8 cm, pulmonary oedema or pleural effu-
sion on chest X-ray, paroxysmal nocturnal dyspnoea, more
than two pillow orthopnoea, and respiratory rate more than
20 breathes per minute). The preliminary data showed no
advantage to UF over adjustable diuretic treatment; also, more
patients in the UF arm experienced adverse events [45]
(Table 1).
The current ESC guidelines suggest ultrafiltration to be
considered on patients who fail diuretic therapy [1•]. It
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remains a therapy that appears promising, but has yet to find a
definitive role. It is possible that it may have a niche applica-
tion in managing patients with very severe and unresponsive
fluid retention, but it is unlikely ever to achieve widespread
use as standard therapy.
Conclusion
The management of patients with AHF is challenging and re-
flects the heterogeneity of patient’s presentation, the complexity
and severity of a multi-organ syndrome, and the limited thera-
peutic options, usually restricted to a combination of diuretics
and vasodilators. Recent trials of novel pharmacological and
non-pharmacological therapies have shown a number of possible
agents that might offer beneficial haemodynamic responses;
however, it is not at all clear that beneficial haemodynamic re-
sponses translate into improved clinical outcomes, whether in
terms of short-term symptom relief or longer-term outcome.
More trials are needed that will have tomeet a number of criteria.
The patients included in a trial must be carefully phenotyped so
we know exactly to whom particular sets of trial results refer;
they must be powered for relevant clinical endpoints (such as
robust markers of symptoms severity, or length of stay); and they
must answer robustly framed questions about outcome (such as
days alive and out of hospital at 6 months).
Compliance with Ethical Standards
Conflict of Interest Drs. Shah, Pellicori, Cuthbert, and Clark have
nothing to report.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1.• Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats
AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA,
Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B,
Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH,
van der Meer P, Authors/Task Force Members; Document
Reviewers. 2016 ESC guidelines for the diagnosis and treatment
of acute and chronic heart failure: the task force for the diagnosis
and treatment of acute and chronic heart failure of the European
Society of Cardiology (ESC) developed with the special contribu-
tion of the Heart Failure Association (HFA) of the ESC. Eur Heart J.
2016;37:2129–200. doi:10.1093/eurheartj/ehw128. These are the
current guidelines for the management of acute heart failure.
2. Shoaib A, Waleed M, Khan S, Raza A, Zuhair M, Kassianides X,
Djahit A, Goode K, Wong K, Rigby A, Clark A, Cleland J.
Breathlessness at rest is not the dominant presentation of patients
admitted with heart failure. Eur J Heart Fail. 2014;16:1283–91. doi:
10.1002/ejhf.153.
3. Pellicori P, Kaur K, Clark AL. Fluid management in patients with
chronic heart failure. Cardiac Failure Review. 2015;1:90–5. doi:10.
15420/cfr.2015.1.2.90.
4.•• Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein
K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF,
Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP,
Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J,
O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR,
Udelson JE, Yancy CW, Zannad F, Gheorghiade M, International
AHFSWorking Group. Clinical trials of pharmacological therapies
in acute heart failure syndromes: lessons learned and directions
forward. Circ Heart Fail. 2010;3:314–25. doi:10.1161/
CIRCHEARTFAILURE.109.893222. Important paper
highlighting the difficulties in conducting trials in acute heart
failure.
5.•• McDonagh TA,KomajdaM,Maggioni AP, Zannad F, Gheorghiade
M,MetraM, Dargie HJ. Clinical trials in acute heart failure: simpler
solutions to complex problems. Consensus document arising from a
European Society of Cardiology cardiovascular round-table think
tank on acute heart failure, 12May 2009. Eur J Heart Fail. 2011;13:
1253–60. doi:10.1093/eurjhf/hfr126. Important paper
highlighting the difficulties in conducting trials in acute heart
failure.
6. Ramírez A, Abelmann WH. Cardiac decompensation. N Engl J
Med. 1974;290:499–501. doi:10.1056/NEJM197402282900906.
7.•• Mentz RJ, Felker GM, Ahmad T, Peacock WF, Pitt B, Fiuzat M,
et al. Learning from recent trials and shaping the future of acute
heart failure trials. Am Heart J. 2013;166:629–35. doi:10.1016/j.
ahj.2013.08.001. Important paper highlighting the difficulties in
conducting trials in acute heart failure.
8. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM,
Ponikowski P, Bloomfield DM, O'Connor CM. Physician-
determined worsening heart failure: a novel definition for early
worsening heart failure in patients hospitalized for acute heart fail-
ure—association with signs and symptoms, hospitalization dura-
tion, and 60-day outcomes. Cardiology. 2010;115:29–36. doi:10.
1159/000249280.
9.• Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW,
Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO,
Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury
AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette
AM, Braunwald E, O’Connor CM. Diuretic strategies in patients
with acute decompensated heart failure. N Engl J Med. 2011;364:
797–805. doi:10.1056/NEJMoa1005419. Important paper
highlighting the use of diuretics in acute heart failure.
10. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC,
Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J,
Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW,
Zannad F, Tavazzi L, Heart Failure Association of ESC (HFA).
EURObservational Research Programme: the Heart Failure Pilot
Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076–84. doi:
10.1093/eurjhf/hfq154.
11.• Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz
A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y,
Zaidenstein R, Golik A. Randomised trial of high-dose isosorbide
Curr Heart Fail Rep (2017) 14:147–157 155
dinitrate plus low-dose furosemide versus high-dose furosemide
plus low-dose isosorbide dinitrate in severe pulmonary oedema.
Lancet. 1998;351:389–93. doi:10.1016/S0140-6736(97)08417-1.
Important paper highlighting the use of nitrates in acute
heart failure.
12. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effective-
ness and relative effectiveness of intravenous inotropic drugs acting
through the adrenergic pathway in patients with heart failure-a me-
ta-regression analysis. Eur J Heart Fail. 2002;4:515–29. doi:10.
1016/S1388-9842(02)00041-7.
13. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE,
Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T,
Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang
PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F,
Anker SD, Rhodes A, McMurray JJ, Filippatos G, European
Society of Cardiology; European Society of Intensive Care
Medicine. Assessing and grading congestion in acute heart failure:
a scientific statement from the acute heart failure committee of the
heart failure association of the European Society of Cardiology and
endorsed by the European Society of Intensive Care Medicine. Eur
J Heart Fail. 2010;12:423–33. doi:10.1093/eurjhf/hfq045.
14. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC,
Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M,
HaughtWH, LeJemtel TH. Intravenous nesiritide, a natriuretic pep-
tide, in the treatment of decompensated congestive heart failure.
Nesiritide Study Group. N Engl J Med. 2000;343:246–53. doi:10.
1056/NEJM200007273430403.
15. Publication Committee for the VMAC Investigators (Vasodilatation
in the Management of Acute CHF). Intravenous nesiritide vs nitro-
glycerin for treatment of decompensated congestive heart failure: a
randomized controlled trial. JAMA. 2002;287:1531–40. doi:10.
1001/jama.287.12.1531.
16. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW,
Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM,
JJ MM, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams
Jr KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler
J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U,
Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D,
Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA,
Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H,
Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh
BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink
JR, Triposkiadis F, Troughton RW, Voors AA,Whellan DJ, Zannad
F, Califf RM. Effect of nesiritide in patients with acute decompen-
sated heart failure. N Engl J Med. 2011;365:32–43. doi:10.1056/
NEJMoa1100171.
17. Forssmann W, Meyer M, Forssmann K. The renal urodilatin sys-
tem: clinical implications. Cardiovasc Res. 2001;51:450–62.
18. Mitrovic V, Lüss H, Nitsche K, Forssmann K, Maronde E, Fricke
K, Forssmann WG, Meyer M. Effects of the renal natriuretic pep-
tide urodilatin (ularitide) in patients with decompensated chronic
heart failure: a double-blind, placebo-controlled, ascending-dose
trial. Am Heart J. 2005;150:1239. doi:10.1016/S0008-6363(01)
00331-5.
19. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M,
Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Lüss H,
MeyerM.Haemodynamic and clinical effects of ularitide in decom-
pensated heart failure. Eur Heart J. 2006;27:2823–32. doi:10.1093/
eurheartj/ehl337.
20. Lüss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristić AD,
Moiseyev VS, Forssmann WG, Hamdy AM, Meyer M. Renal ef-
fects of ularitide in patients with decompensated heart failure. Am
Heart J. 2008;155:1012. doi:10.1016/j.ahj.2008.02.011.
21. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intrave-
nous levosimendan compared with dobutamine in severe low-
output heart failure (the LIDO study): a randomised double-blind
trial. Lancet. 2002;360:196–202. doi:10.1016/S0140-6736(02)
09455-2.
22. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX,
Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE
Investigators. Levosimendan vs dobutamine for patients with acute
decompensated heart failure: the SURVIVE Randomized Trial.
JAMA. 2007;297:1883–91. doi:10.1001/jama.297.17.1883.
23. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J,
Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C,
Huang B, Sarapohja T, REVIVE Heart Failure Study Group.
Effect of levosimendan on the short-term clinical course of patients
with acutely decompensated heart failure. JACCHeart Fail. 2013;1:
103–11. doi:10.1016/j.jchf.2012.12.004.
24. Shah SJ, Blair JE, Filippatos GS,Macarie C, RuzylloW, Korewicki
J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P,
Kremastinos D, Grzybowski J, Valentini G, Sabbah HN,
Gheorghiade M, HORIZON-HF Investigators. Effects of
istaroxime on diastolic stiffness in acute heart failure syndromes:
results from the Hemodynamic, Echocardiographic, and
Neurohormonal Effects of Istaroxime, a Novel Intravenous
Inotropic and Lusitropic Agent: a Randomized Controlled Trial in
Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am
Heart J. 2009;157:1035–41. doi:10.1016/j.ahj.2009.03.007.
25. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA,
Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E,
Teichman SL, Cotter G. Relaxin for the treatment of patients with
acute heart failure (Pre-RELAX-AHF): a multicentre, randomised,
placebo-controlled, parallel-group, dose-finding phase IIb study.
Lancet. 2009;373:1429–39. doi:10.1016/S0140-6736(09)60622-
X.
26. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G,
Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams Jr
KF, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J,
Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R,
Schumacher C, Severin TM, Metra M, RELAXin in Acute Heart
Failure (RELAX-AHF) Investigators. Serelaxin, recombinant hu-
man relaxin-2, for treatment of acute heart failure (RELAX-AHF):
a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
doi:10.1016/S0140-6736(12)61855-8.
27. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G,
Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams Jr
KF, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J,
Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL,
Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink
JR, RELAX-AHF Investigators. Effect of serelaxin on cardiac, re-
nal, and hepatic biomarkers in the Relaxin in Acute Heart Failure
(RELAX-AHF) development program: correlation with outcomes.
J Am Coll Cardiol. 2013;61:196–206. doi:10.1016/j.jacc.2012.11.
005.
28. Felker GM, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz
JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Soergel DG,
Teerlink JR, Violin JD, Voors AA, Pang PS. Heart failure therapeu-
tics on the basis of a biased ligand of the angiotensin-2 type 1
receptor. Rationale and design of the BLAST-AHF study (Biased
Ligand of the Angiotensin Receptor Study in Acute Heart Failure).
JACC Heart Fail. 2015;3:193–20. doi:10.1016/j.jchf.2014.09.008.
29. Soergel D, Subach RA, James IE, Cowan CL, Gowen M, Lark M.
TRV027, a beta-arrestin biased ligand at the angiotensin 2 type 1
receptor, produces rapid, reversible changes in hemodynamics in
patients with stable systolic heart failure. J Am Coll Cardiol.
2013;61(Suppl 10):e683.
30. Teerlink JR, Felker GM, McMurray JJ, Ponikowski P, Metra M,
Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JG, Kim JB, Lei
L, Knusel B, Wolff AA, Malik FI, Wasserman SM, ATOMIC-AHF
Investigators. Acute treatment with Omecamtiv Mecarbil to in-
crease contractility in acute heart failure: the ATOMIC-AHF study.
156 Curr Heart Fail Rep (2017) 14:147–157
J Am Coll Cardiol. 2016;67:1444–55. doi:10.1016/j.jacc.2016.01.
031.
31. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor
CM, Metra M, Massie BM, Protect Steering Committee,
Investigators, and Coordinators. The PROTECT pilot study: a ran-
domized, placebo-controlled, dose-finding study of the adenosine
A1 receptor antagonist rolofylline in patients with acute heart fail-
ure and renal impairment. J Card Fail. 2008;14:631–40. doi:10.
1016/j.cardfail.2008.08.010.
32. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR,
Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A,
DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich
HC, PROTECT Investigators and Committees. Rolofylline, an
adenosine A1-receptor antagonist, in acute heart failure. N Engl J
Med. 2010;363:1419–28. doi:10.1056/NEJMoa0912613.
33. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A.
Renal vasodilatory action of dopamine in patients with heart failure:
magnitude of effect and site of action. Circulation. 2008;117:200–5.
doi:10.1161/CIRCULATIONAHA.107.737106.
34. Chen HH, AnstromKJ, GivertzMM, Stevenson LW, SemigranMJ,
Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM,
Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH,
Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM,
Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL,
Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee
KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM,
NHLBI Heart Failure Clinical Research Network. Low-dose dopa-
mine or low-dose nesiritide in acute heart failure with renal dys-
function: the ROSE acute heart failure randomized trial. JAMA.
2013;310:2533–43. doi:10.1001/jama.2013.282190.
35. Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis
C, Rovithis D, Economou D, Savvatis K, Kirlidis T, Tsaknakis T,
Skoularigis J, Westermann D, Tschöpe C, Triposkiadis F. Impact of
dopamine infusion on renal function in hospitalized heart failure
patients: results of the Dopamine in Acute Decompensated Heart
Failure (DAD-HF) trial. J Card Fail. 2010;16:922–30. doi:10.1016/
j.cardfail.2010.07.246.
36. Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G,
Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K,
Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C,
Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas
G, Karvounis H, Kalogeropoulos AP, Giamouzis G. Efficacy and
safety of high dose versus low dose furosemide with or without
dopamine infusion: the Dopamine in Acute Decompensated Heart
Failure II (DAD-HF II) trial. Int J Cardiol. 2014;172:115–21. doi:
10.1016/j.ijcard.2013.12.276.
37. KonstamMA, GheorghiadeM, Burnett Jr JC, Grinfeld L,Maggioni
AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J,
Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in
Heart Failure Outcome Study With Tolvaptan (EVEREST)
Investigators. Effects of oral tolvaptan in patients hospitalized for
worsening heart failure: the EVEREST Outcome Trial. JAMA.
2007;297:1319–31. doi:10.1001/jama.297.12.1319.
38. Felker GM,Mentz RJ, Cole R, Adams KF, Egnaczyk GF, Fiuzat M,
Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P,
Roberts R, O'Connor CM. Efficacy and safety of tolvaptan in pa-
tients hospitalizedwith acute heart failure. J AmColl Cardiol. 2016;
doi:10.1016/j.jacc.2016.09.004.
39. Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on
left ventricular function and filling pressures in patients with and
without congestive heart failure. Chest. 2001;120:467–73. doi:10.
1378/chest.120.2.467.
40. GrayA, Goodacre S, NewbyDE,MassonM, Sampson F, Nicholl J,
3CPO Trialists. Noninvasive ventilation in acute cardiogenic pul-
monary edema. N Engl J Med. 2008;359:142–51. doi:10.1056/
NEJMoa0707992.
41. Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, Chen YW, He
QY. Meta-analysis: noninvasive ventilation in acute cardiogenic
pulmonary edema. Ann Intern Med. 2010;152:590–600. doi:10.
7326/0003-4819-152-9-201005040-00009.
42. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure
ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary
oedema. Cochrane Database Syst Rev. 2013;5. doi: 10.1002/
14651858
43. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA,
Ultrafiltration Versus Intravenous Diuretics for Patients
Hospitalized for Acute Decompensated Heart Failure (UNLOAD)
Investigators. Ultrafiltration is associated with fewer
rehospitalizations than continuous diuretic infusion in patients with
decompensated heart failure: results from UNLOAD. J Card Fail.
2010;16:277–84. doi:10.1016/j.cardfail.2009.12.009.
44. Bart BA, Goldsmith SR, Lee KL, GivertzMM, O'Connor CM, Bull
DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili
EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH,
Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra
JC, Mascette AM, Braunwald E, Heart Failure Clinical Research
Network. Ultrafiltration in decompensated heart failure with
cardiorenal syndrome. N Engl J Med. 2012;367:2296–304. doi:
10.1056/NEJMoa1210357.
45. Costanzo MR, Negoianu D, Jaski BE, Bart BA, Heywood JT,
Anand IS, Smelser JM, Kaneshige AM, Chomsky DB, Adler ED,
Haas GJ, Watts JA, Nabut JL, Schollmeyer MP, Fonarow GC.
Aquapheresis versus intravenous diuretics and hospitalizations for
heart failure. JACC Heart Fail. 2016;4:95–105. doi:10.1016/j.jchf.
2015.08.005.
Curr Heart Fail Rep (2017) 14:147–157 157
